Gordana Wozniak | Head of CD Laboratory for Innovative Immunotherapeutics
University of Natural Resources and Life Sciences (BOKU) Vienna

Gordana Wozniak, Head of CD Laboratory for Innovative Immunotherapeutics, University of Natural Resources and Life Sciences (BOKU) Vienna

Dr. Gordana Wozniak Knopp has received her PhD in Biochemistry and Molecular Biology from Medical University of Ljubljana, Slovenia. In her post-doctoral studies at the University of Natural Resources and Life Sciences (BOKU), Vienna, she got acquainted with display library methods and development of alternative scaffolds for antigen recognition.  She actively participated to the development of Fcab technology, which is based on the introduction of a novel antigen binding site into an Fc fragment scaffold as well as its implementation as a part of bispecific antibodies, and is one of the co-founders of F-star, today a clinical-stage NASDAQ-listed company. She holds several patents and patent applications from the field of antibody engineering. Since 2016, she is heading Christian Doppler Laboratory for Innovative Immunotherapeutics at BOKU.


Festival of Biologics Day 1 @ 17:30

Trispecific antibodies developed with modular antibody technology

  • Multispecific antibodies are bound to make a difference to human health, regarding their versatile use as soluble agents or effector cell-bound entities
  • A symmetric Ig-like bispecific antibody mAb2 format, featuring a second antigen binding site in the Fc fragment, has been developed to the stage of clinical testing, with currently three candidate molecules in trials
  • Based on this format, chemically composed trispecific antibodies have been prepared using controlled Fab-arm exchange. Resulting molecules were of good biophysical characteristics and retained antigen reactivity and biological activity of the parental mAb2 constructs.
last published: 01/Jul/22 16:05 GMT

back to speakers